SureTrader Stock Hero Advertisement SureTrader
Home > Boards > US OTC > Medical - Drugs >

Elite Pharmaceuticals (ELTP)

ELTP RSS Feed
Add ELTP Price Alert      Hide Sticky   Hide Intro
Moderator: No Moderator Mocha Jet, Drugdoctor, RizZo, lasers, John_Langston, IB_
Search This Board:
Last Post: 5/23/2015 1:56:47 AM - Followers: 669 - Board type: Free - Posts Today: 5

Elite Pharmaceuticals is a specialty pharmaceutical company specializing in niche generics and committed to the development of abuse-deterrent opioids to help curb diversion, misuse and abuse.  Elite has a pipeline of opioid abuse-deterrent products under development utilizing the company’s proprietary pharmacological abuse-deterrent technology.

 
Elite’s website can be found by going to http://www.elitepharma.com


How ART Works:

Elite’s proprietary abuse-deterrent technology, ART™, is a multi-particulate capsule which contains an opioid agonist in addition to naltrexone, an opioid antagonist used primarily in the management of alcohol dependence and opioid dependence. When this product is taken as intended, the naltrexone is designed to pass through the body unreleased while the opioid agonist releases over time providing therapeutic pain relief for which it is prescribed. If the multi-particulate beads are crushed or dissolved, the opioid antagonist, naltrexone, is designed to release. The absorption of the naltrexone is intended to block the euphoria by preferentially binding to same receptors in the brain as the opioid agonist and thereby reducing the incentive for abuse or misuse by recreational drug abusers. Elite’s pharmacological approach to abuse-deterrence can be applied to a wide range of opioids used today in pain management.
 


 

Recent Press Releases:

Apr 21, 2015
Elite Pharmaceuticals Announces Launch Of Generic Hydroxyzine Tablets
http://ir.elitepharma.com/profiles/investor/ResLibraryView.asp?ResLibraryID=76601&BzID=2258&t=1948&g=939&Nav=0&LangID=1&s=0


Feb 17, 2015
Elite Pharmaceuticals Provides Guidance On Phase III Study For ELI-200
http://ir.elitepharma.com/profiles/investor/ResLibraryView.asp?ResLibraryID=75450&GoTopage=1&Category=2163&BzID=2258&t=1948&G=939

Jan, 15 2015
Elite Pharmaceuticals Announces First Shipment Of Generic Isradipine Capsules
http://ir.elitepharma.com/profiles/investor/ResLibraryView.asp?ResLibraryID=74835&GoTopage=1&Category=2163&BzID=2258&t=1948&G=939

More information can be found by going to Elite’s investor section:  http://ir.elitepharma.com/press_releases
Highlights From Last Quarter:

Third Quarter ending December 31, 2014
♦  Consolidated revenues for the third quarter of Fiscal 2015 continued their upward trend, rising to $1.4 million, an increase of approximately 8.5% over consolidated revenues for the second quarter of Fiscal 2015. The third quarter revenues for this year were $0.3 million below revenues reported for the third quarter of the prior fiscal year due to a one-time $0.6 million milestone that occurred in the prior year third quarter. Development of our proprietary abuse-deterrent opioid technology continues to be Elite's top priority. During the quarter, Elite invested an additional $2.3 million in clinical trials and other product development activities.

Highlights for the third quarter
♦  As of December 31, our working capital was $8.9 million, including cash of $8.3 million.
♦  Isradipine was recently launched, and we expect to introduce Hydroxyzine and Dantrolene in the near-term.
♦  We're a penny stock company with eyes on NASDAQ; we need to be Sarbanes Oxley compliant. So we are evaluating the gaps that we have by hiring consultants and external consultants in order to evaluate the checks and      balances we have in order for us to get there.
♦  We are creating infrastructure in our facilities with expanding the facilities and adding new equipment and upgrading the current equipment in order to support our (Eli-200) product launch.
2014 was our best year, 2015 will be the year we file our first ART product, and Q1 2016 will be the year we launch our first ART product and hopefully will be the year we will be on NASDAQ.

Nine-Month Period Ending December 31, 2014
♦  Revenues for the nine months ending December 31, 2014 were $3.8 million, an increase of 6% over revenues for the comparable period of the prior year, even with the one-time milestone being included in the prior year revenues. The increase in revenues is due to the continued growth and expansion of Elite's generic product lines.
♦  During the first nine months of the fiscal year, Elite has invested a total of $9.9 million in product development, including successful completion of the human abuse liability study for ELI-200.
Financials:

 

Products:
http://www.elitepharma.com/products/

Leadership:

President & Chief Executive Officer - Nasrat Hakim

Nasrat Hakim joined Elite in August 2013 as Director, President and Chief Executive Officer. Mr. Hakim has more than 30 years of pharmaceutical and medical industry experience in Quality Assurance, Analytical Research and Development, Technical Services and Regulatory Compliance. He brings with him proven management experience, in-depth knowledge of manufacturing systems, development knowledge in immediate and extended release formulations and extensive regulatory experience of GMP and FDA regulations. Prior to his leading Elite, from 2004 to 2013, Mr. Hakim was employed by Actavis, Watson and Alpharma in various senior management positions. Most recently, Mr. Hakim served as International Vice President of Quality Assurance at Actavis, overseeing 25 sites with more than 3,000 employees under his leadership. Mr. Hakim also served as Corporate Vice President of Technical Services, Quality and Regulatory Compliance for Actavis U.S., Global Vice President, Quality and Regulatory Compliance for Alpharma, as well as Executive Director of Quality Unit at TheraTech, overseeing manufacturing and research and development. In 2009, Mr. Hakim founded Mikah Pharma, LLC, a virtual, fully functional pharmaceutical company.

Mr. Hakim’s career started in Medical Laboratory Technology from the Academy of Health and Sciences in the U.S. Army based in San Antonio, TX, followed by Graduate Certification in Regulatory Affairs (RAC) from California State University at Sacramento, Sacramento, CA; Bachelor in Chemistry/Bio-Chemistry and Masters of Science in Chemistry from California State University at Sacramento, Sacramento, CA; and a Masters in Law with Graduate Certification in U.S. Taxation from St. Thomas University, School of Law, Miami, FL.

Board of Directors Chairman - Jerry Treppel

Mr. Treppel is currently a Managing Director of ArcLight Advisors, an investment bank specializing in the health care sector. From October 2008 through March 2013, Mr. Treppel was Managing Director of Ledgemont Capital Group LLC, a boutique merchant bank that provided access to capital and corporate advisory services to public and private companies. Additionally, he served as the managing member of Wheaten Capital Management LLC, a capital management company focusing on investments in the health care sector from 2003 to 2008. Over the past 20 years, Mr. Treppel was an equity research analyst focusing on the specialty pharmaceuticals and generic drug sectors at several investment banking firms including Banc of America Securities, Warburg Dillon Read LLC (now UBS), and Kidder Peabody and Co. He previously served as a healthcare services analyst at various firms, including Merrill Lynch & Co. Mr. Treppel holds a BA in Biology from Rutgers College, an MHA in Health Administration from Washington University, and an MBA in Finance from New York University. Mr. Treppel has been a Chartered Financial Analyst *CFA) since 1988.


Investor Relations:

Vice President of Investor Relations and Corporate - Dianne Will

Dianne Will joined Elite in 2003 as an Investor Relations Specialist and was named Elite’s Vice President of Investor Relations and Corporate Affairs in 2013. In 1996, Ms. Will founded Willstar Consultants, an investor relations consulting firm and has been providing investor relations services to a range of public companies for more than 19 years with a primary focus in the pharmaceutical and tech sectors. Her firm provides corporate services including management and execution of investor relations programs, investor communication, peer research, compliance services, support for
management team changes, proxy fights, crisis management and IPOs.

Investor Relations and Corporate Inquiries

Dianne Will
Vice President of Investor Relations and Corporate Affairs
Telephone: 518-398-6222
Email: dianne@elitepharma.com

Corporate Headquarters

165 Ludlow Avenue
Northvale, New Jersey 07647
Phone: 201-750-2646
Fax: 201-750-2755
 


Miscellaneous Links:

SEC Filings: http://www.sec.gov/cgi-bin/browse-edgar?action=getcompany&CIK=0001053369&owner=include

FDA website: http://www.accessdata.fda.gov/scripts/cder/drugsatfda/index.cfm?fuseaction=Search.DrugDetails

Clinical Trials.Gov: https://www.clinicaltrials.gov/




 

                                             ELTP Potential Share Price in Relation to Percentage of Pain Market Captured



  • 1D
  • 1M
  • 2M
  • 3M
  • 6M
  • 1Y
  • 2Y
  • 3Y
  • 5Y
ELTP
Current Price
Volume:
Bid Ask Day's Range
Wiki
ELTP News: Statement of Changes in Beneficial Ownership (4) 05/21/2015 03:03:54 PM
ELTP News: Amended Statement of Changes in Beneficial Ownership (4/a) 05/21/2015 02:43:42 PM
ELTP News: Amended Statement of Changes in Beneficial Ownership (4/a) 05/13/2015 07:53:38 PM
ELTP News: Amended Statement of Changes in Beneficial Ownership (4/a) 05/13/2015 07:38:01 PM
ELTP News: Statement of Changes in Beneficial Ownership (4) 05/13/2015 07:24:17 PM
PostSubject
#148487  Sticky Note Ya-don't-say???-Trial-record-1 of-66-for:-eli-200 Drugdoctor 03/21/15 11:04:27 AM
#142585  Sticky Note Great info! This is the beginning of a Dr Speculator Ninja 01/29/15 02:56:03 PM
#142438  Sticky Note FOR THOSE WANTING A DEEPER UNDERSTANDING OF WHY Couch 01/28/15 07:17:31 PM
#106205  Sticky Note Elite’s 1st Generation Triple Patents and their Purpose lasers 04/30/14 08:50:54 AM
#154591   Co-defendant Abbott Labs has not responded either.... Jimmy Joe 05/23/15 01:56:47 AM
#154590   http://globenewswire.com/news-release/2015/02/17/707247/10120689/en/Elite-Pharma newguy11 05/23/15 01:54:12 AM
#154589   Snup dog... different but nicely said. Jimmy Joe 05/23/15 01:34:18 AM
#154588   Rich like comparing roller skates to apples. If Jimmy Joe 05/23/15 01:31:40 AM
#154587   Good, that means my returns will be even mrwrn2010 05/23/15 12:06:04 AM
#154585   Maybe that is because they have lawyers and richme 05/22/15 10:40:51 PM
#154584   There is always an ingenues way of stating richme 05/22/15 10:19:31 PM
#154583   Yes and your and the PPS is much richme 05/22/15 09:59:09 PM
#154582   Can't sustain .25, no need to think .97. richme 05/22/15 09:55:55 PM
#154581   3.35:-) kennyt 335 05/22/15 09:39:49 PM
#154580   How much higher than $0.97? NASDAQ2020 05/22/15 09:00:47 PM
#154579   And yet the PPS is above the .125 Couch 05/22/15 08:30:15 PM
#154577   Correct and they have approved a lot of Couch 05/22/15 08:26:43 PM
#154576   Or .02 that has never transpired and never Couch 05/22/15 08:22:37 PM
#154574   Truth is that the FDA has never recognized richme 05/22/15 07:30:58 PM
#154573   I know and neither did the .64, .34; richme 05/22/15 07:27:00 PM
#154572   ELTP Memorial Day Special: sharpei 05/22/15 07:25:53 PM
#154571   Oh, Oh, But, But, Elites generics, I mean richme 05/22/15 07:24:34 PM
#154570   I only buy stocks I like or love. NASDAQ2020 05/22/15 07:09:42 PM
#154569   I'm sure ELTP will explode higher with the FDA-approval. John_Langston 05/22/15 06:41:27 PM
#154568   It's the GOVERNMENT! John_Langston 05/22/15 04:58:22 PM
#154567   Seems like a lame excuse to me. John_Langston 05/22/15 04:55:28 PM
#154566   Or 26.5¢ that did transpire!!! John_Langston 05/22/15 04:52:46 PM
#154565   ELTP has had it's 2300% ROI already. John_Langston 05/22/15 04:50:49 PM
#154564   So if so much pressure is being placed John_Langston 05/22/15 04:45:53 PM
#154563   Even though most trades continue to be sells John_Langston 05/22/15 04:39:25 PM
#154562   tenor, tenor....It's the GOVERNMENT! No further explanation sharpei 05/22/15 04:10:48 PM
#154561   Nuts. Why should it take 7 weeks tenor15824 05/22/15 04:06:21 PM
#154560   Congratulatios, utamaro. You'll enjoy a fabulous MD sharpei 05/22/15 03:52:43 PM
#154559   Yeah just like the selling at .125 hype Couch 05/22/15 03:49:01 PM
#154558   Im trying to figure out just how long utamaro71 05/22/15 03:47:50 PM
#154557   Who says the FDA has delayed anything further. Couch 05/22/15 03:46:45 PM
#154556   And at the same time ELTP keeps tanking richme 05/22/15 03:41:50 PM
#154555   It is articles like this that cause me tenor15824 05/22/15 03:40:16 PM
#154554   Have A Happy Memorial Day....A Day To Remember conix 05/22/15 03:30:29 PM
#154553   ELTP Chart May 22 sharpei 05/22/15 03:29:23 PM
#154552   Yep. It's all psychology. Nothing wrong with the mrwrn2010 05/22/15 03:23:21 PM
#154550   Likewise! Will be waiting in the wings in mrwrn2010 05/22/15 03:20:17 PM
#154549   The continued pressure placed on governmental agencies to Couch 05/22/15 03:11:09 PM
#154546   Couch- Nice post. ANd it is for all mts 05/22/15 12:21:44 PM
#154545   Then why don't you? Serious question. I've been Couch 05/22/15 12:04:50 PM
#154544   I look forward to seeing more former Longs sharpei 05/22/15 11:54:28 AM
#154543   On the contrary, ELTP is a STRONG BUY Aqua 05/22/15 11:51:00 AM
#154542   I haven't found any trustworthy info on ELI202 IB_ 05/22/15 11:40:16 AM
#154541   Im thinking of more shares at this level. NASDAQ2020 05/22/15 11:28:46 AM
#154540   (joke) At 77 and getting older each day, SCHH 05/22/15 11:16:40 AM
#154538   I still own shares, but thinking of selling them.. cicle1 05/22/15 10:48:15 AM
#154537   Interest in buying Elite is dwindling to about IB_ 05/22/15 10:44:29 AM
#154534   Great reading material for a long weekend. Thanx Couch! NASDAQ2020 05/22/15 07:18:03 AM
#154533   Another down day- what a surprise! jtf3 05/22/15 12:37:15 AM
PostSubject